The European Mediscience Awards, sponsored by Kempen & Co, is the largest annual gathering of private and publicly quoted healthcare, biotech and life sciences companies in Europe. It celebrates the best in the sector and highlights the achievements of individuals and companies. The event recognises the importance of the capital markets to fund growth and innovation. The awards cover the period 1 April 2013 to 31 March 2014.
Dr. Darrin M. Disley, Chief Executive Officer of Horizon Discovery, commented: “We are delighted to have been awarded the Emerging Star Award at the 2014 European Mediscience Awards. The past year has been transformational for Horizon and has seen the Company develop from a fast growing private business to become a successfully listed international company with over 800 customers globally. Horizon is at the forefront of a gene editing market that is set to grow to more than £29 billion by 2015. With our disruptive, world-leading technology and strong IP position, Horizon is positioned to become the global market-leader in the provision of translational genomics research tools and services.”
About Horizon Discovery
Horizon (LSE: HZD) is a revenue-generating life science company supplying research tools to organizations engaged in genomics research and the development of personalized medicines. Horizon has a diverse and international customer base approaching 800 organizations, including major pharmaceutical, biotechnology and diagnostic companies as well as leading academic research centers. The Company supplies its products and services into multiple markets, estimated to total in excess of £29 billion by 2015.
Horizon’s core capabilities are built around its proprietary translational genomics platform, GENESIS™, a high-precision and flexible suite of gene editing tools able to alter almost any endogenous gene sequence of human or mammalian cell-lines. Horizon has applied GENESIS™ to create over 550 X-MAN™ cell lines, accurately modeling the disease-causing mutations found in genetically based diseases. These ‘patients-in-a-test-tube’ are being used by customers to identify the effect of individual or compound genetic mutations on drug activity, patient responsiveness, and resistance, which may lead to the successful prediction of which patient sub-groups will respond to currently available and future drug treatments.
In addition, Horizon provides GENASSIST™ CRISPR and rAAV gene editing tools, custom cell line generation services for research and bioproduction applications, quantitative molecular reference standards, contract research and custom screening services, haploid cell lines (through Horizon’s partner Haplogen), and custom shRNA development services and off-the-shelf validated shRNA (through Horizon’s partner Sirion).
Horizon is headquartered in Cambridge, UK, and is listed on the London Stock Exchange’s AIM market under the ticker “HZD”, for further information please visit: www.horizondiscovery.com
*******
For further information from Horizon Discovery Group Plc, please contact:
Consilium Strategic Communications (Financial Media and Investor Relations)
Amber Bielecka / Mary-Jane Elliott / Jessica Hodgson / Matthew Neal
Tel: +44 (0) 20 3709 5701
Email: horizon@consilium-comms.com
Zyme Communications (Trade and Regional Media)
Katie Odgaard/Lorna Cuddon
Tel: +44 (0)7787 502 947 / +44 (0)7811 996 942
Email: katie.odgaard@zymecommunications.com / lorna.cuddon@zymecommunications.com
____________________________________________________________